196 related articles for article (PubMed ID: 27196771)
1. Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.
Awuah P; Bera TK; Folivi M; Chertov O; Pastan I
Mol Cancer Ther; 2016 Jul; 15(7):1648-55. PubMed ID: 27196771
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.
Alewine C; Xiang L; Yamori T; Niederfellner G; Bosslet K; Pastan I
Mol Cancer Ther; 2014 Nov; 13(11):2653-61. PubMed ID: 25239937
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding.
Zhang Y; Chertov O; Zhang J; Hassan R; Pastan I
Cancer Res; 2011 Sep; 71(17):5915-22. PubMed ID: 21775520
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.
Bauss F; Lechmann M; Krippendorff BF; Staack R; Herting F; Festag M; Imhof-Jung S; Hesse F; Pompiati M; Kollmorgen G; da Silva Mateus Seidl R; Bossenmaier B; Lau W; Schantz C; Stracke JO; Brinkmann U; Onda M; Pastan I; Bosslet K; Niederfellner G
Mol Oncol; 2016 Oct; 10(8):1317-29. PubMed ID: 27507537
[TBL] [Abstract][Full Text] [Related]
5. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
Cerise A; Bera TK; Liu X; Wei J; Pastan I
Clin Colorectal Cancer; 2019 Sep; 18(3):192-199.e1. PubMed ID: 31345777
[TBL] [Abstract][Full Text] [Related]
6. Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy.
Bera TK; Liu W; Leshem J; King E; Kozlov S; Pastan I
J Immunother; 2019 May; 42(4):119-125. PubMed ID: 30933045
[TBL] [Abstract][Full Text] [Related]
7. Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors.
Hagerty BL; Pegna GJ; Xu J; Tai CH; Alewine C
Biomolecules; 2020 Jun; 10(7):. PubMed ID: 32605175
[TBL] [Abstract][Full Text] [Related]
8. Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.
Leshem Y; O'Brien J; Liu X; Bera TK; Terabe M; Berzofsky JA; Bossenmaier B; Niederfellner G; Tai CH; Reiter Y; Pastan I
Cancer Immunol Res; 2017 Aug; 5(8):685-694. PubMed ID: 28674083
[TBL] [Abstract][Full Text] [Related]
9. Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes.
Kolyvas E; Rudloff M; Poruchynsky M; Landsman R; Hollevoet K; Venzon D; Alewine C
Oncotarget; 2017 Feb; 8(6):9189-9199. PubMed ID: 27999204
[TBL] [Abstract][Full Text] [Related]
10. Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1.
Ali-Rahmani F; FitzGerald DJ; Martin S; Patel P; Prunotto M; Ormanoglu P; Thomas C; Pastan I
Cancer Res; 2016 Mar; 76(6):1560-8. PubMed ID: 26719540
[TBL] [Abstract][Full Text] [Related]
11. Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.
Filpula D; Yang K; Basu A; Hassan R; Xiang L; Zhang Z; Wang M; Wang QC; Ho M; Beers R; Zhao H; Peng P; Zhou J; Li X; Petti G; Janjua A; Liu J; Wu D; Yu D; Zhang Z; Longley C; FitzGerald D; Kreitman RJ; Pastan I
Bioconjug Chem; 2007; 18(3):773-84. PubMed ID: 17346030
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response.
Zhang J; Khanna S; Jiang Q; Alewine C; Miettinen M; Pastan I; Hassan R
Clin Cancer Res; 2017 Mar; 23(6):1564-1574. PubMed ID: 27635089
[No Abstract] [Full Text] [Related]
13. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.
Hassan R; Broaddus VC; Wilson S; Liewehr DJ; Zhang J
Clin Cancer Res; 2007 Dec; 13(23):7166-71. PubMed ID: 18056197
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors.
Liu XF; Xiang L; FitzGerald DJ; Pastan I
Mol Cancer Ther; 2014 Jan; 13(1):82-9. PubMed ID: 24145282
[TBL] [Abstract][Full Text] [Related]
15. Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody-drug conjugates from synthetic antibody libraries.
Hsu HJ; Tung CP; Yu CM; Chen CY; Chen HS; Huang YC; Tsai PH; Lin SI; Peng HP; Chiu YK; Tsou YL; Kuo WY; Jian JW; Hung FH; Hsieh CY; Hsiao M; Chuang SS; Shen CN; Wang YA; Yang AS
Sci Rep; 2021 Jul; 11(1):15430. PubMed ID: 34326410
[TBL] [Abstract][Full Text] [Related]
16. Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.
Zhang Y; Xiang L; Hassan R; Pastan I
Proc Natl Acad Sci U S A; 2007 Oct; 104(43):17099-104. PubMed ID: 17940013
[TBL] [Abstract][Full Text] [Related]
17. Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line.
Hollevoet K; Mason-Osann E; Müller F; Pastan I
PLoS One; 2015; 10(3):e0122462. PubMed ID: 25803818
[TBL] [Abstract][Full Text] [Related]
18. Multiple proteases are involved in mesothelin shedding by cancer cells.
Liu X; Chan A; Tai CH; Andresson T; Pastan I
Commun Biol; 2020 Dec; 3(1):728. PubMed ID: 33262421
[TBL] [Abstract][Full Text] [Related]
19. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.
Weldon JE; Xiang L; Zhang J; Beers R; Walker DA; Onda M; Hassan R; Pastan I
Mol Cancer Ther; 2013 Jan; 12(1):48-57. PubMed ID: 23136186
[TBL] [Abstract][Full Text] [Related]
20. Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody.
Du X; Xiang L; Mackall C; Pastan I
Clin Cancer Res; 2011 Sep; 17(18):5926-34. PubMed ID: 21813632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
